NSECertificate under SEBI (Depositories and Participants) Regulations, 20187 Oct 2026 · 7 Oct 2026, 01:18 pm
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Bal Pharma Limited · BALPHARMA
✦ AI Summary
Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Bal Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th September 2026
Attachments (1)
📄pdf
Download →
BALPHARMA1_07102026131801_Reg_74_Final_.pdf
View document text
To To Date: October 07, 2026
Listing Compliance Department BSE Limited
National Stock Exchange of India Limited, 1st Floor, New Trading Ring,
Exchange Plaza, 5th Floor, Plot No. C/2, G Block, Rotunda Building, P.J.
Bandra Kurla Complex, Bandra (E), Towers,
Mumbai-400051 Dalal Street,
Mumbai – 400001
Symbol: BALPHARMA Scrip Code: 524824
Sub: Confirmation as per Regulation 74(5) of SEBI (DP) Regulations.
Dear Sir/Madam,
With reference to the above and based on the certificate enclosed herewith, received from our
Registrar and Transfer Agent, MUFG Intime India Private Limited, we hereby confirm that the
details of securities dematerialised/rematerialised during the quarter ended 30th September
2026 have been duly furnished to all the Stock Exchanges where the equity shares of the Company
are listed, within the prescribed time limit.
We further confirm that the share certificates received for dematerialisation, wherever applicable,
have been duly verified, mutilated and cancelled, and the name of the relevant Depository has
been substituted in the records of the Company as the registered owner, within 15 days from the
date of receipt of the certificate of security.
Please takes this intimation on your records
Thanking You.
For Bal Pharma Limited
Shreepada ML
Company Secretary and Compliance officer
ICSI M No : A66681
Enclosure: As above
MUFG Intime India Private Limited
(Formerly Link Intime India Private
Limited)
CIN: U67190MH1999PTC118368
Registered Address:
C-101, Embassy 247, L.B.S. Marg,
Vikhroli (West), Mumbai - 400 083
Tel: +91 22 4918 6000
www.in.mpms.mufg.com
Date: October 07,2026
Bal Pharma Limited
5th Floor Lakshmi Narayan Complex,
10/1 Palace Road Bengaluru, Chickpet,
Bangalore South, Karnataka, India, 560053
Kind Attn: CS Shreepada ML – Company Secretary
Dear Madam,
Sub: Confirmation Certificate under Regulation 74(5) of Securities and Exchange Board of
India (Depositories and Participants) Regulation, 2018.
In reference to the above captioned regulation, we hereby confirm that the securities received from
the depository participants for dematerialisation during the quarter ended 30th September 2026 were
confirmed to the depositories by us and that securities comprised in the said certificates have been
listed on the stock exchanges where the earlier issued securities are listed.
We hereby also confirm that the security certificates received for dematerialisation have been
confirmed after due verification by the depository participant and the name of the depositories have
been substituted in the register of members as the registered owner within the prescribed timelines.
We request you to kindly take note of the above in your records.
Thanking you,
Yours faithfully,
For MUFG Intime India Private Limited
(Formerly Link Intime India Private Limited)
[Deepak Tambe]
Asst. Vice President
MUFG Intime India Private Limited
A Part of MUFG Corporate Markets, a division of MUFG Pension & Market Services